Skip to main content
Top

Clinical & Experimental Metastasis

Issue 2/2004

Content (9 Articles)

Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications

Gaetano Leto, Francesca M. Tumminello, Marilena Crescimanno, Carla Flandina, Nicola Gebbia

A small molecule antagonist of the α v β3 integrin suppresses MDA-MB-435 skeletal metastasis

John F. Harms, Danny R. Welch, Rajeev S. Samant, Lalita A. Shevde, Mary E. Miele, Geetha R. Babu, Steven F. Goldberg, Virginia R. Gilman, Donna M. Sosnowski, Dianalee A. Campo, Carol V. Gay, Lynn R. Budgeon, Robin Mercer, Jennifer Jewell, Andrea M. Mastro, Henry J. Donahue, Nuray Erin, Michael T. Debies, William J. Meehan, Amy L. Jones, Gabriel Mbalaviele, Allen Nickols, Neil D. Christensen, Robert Melly, Lisa N. Beck, Julia Kent, Randall K. Rader, John J. Kotyk, M.D. Pagel, William F. Westlin, David W. Griggs

Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247

Kristen E. Shannon, Jeffery L. Keene, Steven L. Settle, Tiffany D. Duffin, Maureen A. Nickols, Marisa Westlin, Sally Schroeter, Peter G. Ruminski, David W. Griggs

Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: Role of cyclooxygenase-2

Ryan G. Holzer, Randall E. Ryan, Matt Tommack, Eric Schlekeway, Cheryl L. Jorcyk

Angiogenic and antiangiogenic balance regulates concomitant antitumoral resistance

O. Graciela Scharovsky, M. Mercedes Binda, Viviana R. Rozados, Sunita Bhagat, Michael L. Cher, R. Daniel Bonfil

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine